Protein Engineering Market Report 2026

The protein engineering market size has grown rapidly in recent years. It will grow from $4.62 billion in 2025 to $5.31 billion in 2026 at a compound annual growth rate (CAGR) of 14.8%. The growth in the historic period can be attributed to expansion of biopharmaceutical research activities, increasing availability of advanced laboratory instruments, growth in academic protein research, rising investments in biotechnology, improvements in protein characterization methods.

The protein engineering market size is expected to see rapid growth in the next few years. It will grow to $9.3 billion in 2030 at a compound annual growth rate (CAGR) of 15.1%. The growth in the forecast period can be attributed to increasing demand for next-generation biologics, expansion of personalized medicine, growing use of engineered proteins in vaccines, rising adoption of computational biology, increasing collaboration between industry and academia. Major trends in the forecast period include increasing adoption of rational protein design techniques, rising use of ai in protein modeling, growing demand for engineered therapeutic proteins, expansion of custom protein engineering services, enhanced integration of bioinformatics tools.

The escalating demand for protein-based drugs is a key driver fueling the growth of the protein engineering market. These drugs, derived from proteins and utilized for therapeutic purposes, are genetically engineered versions of naturally occurring human proteins. Protein engineering techniques involve modifying protein sequences by altering nucleotides within their encoding genes. This alteration aims to tailor protein-based drugs to specific applications, optimizing their effectiveness. For instance, a study published in the Lancet Diabetes and Endocrinology journal forecasts a 20% increase, reaching nearly 80 million individuals requiring insulin for type-2 diabetes by 2030. This burgeoning demand underscores the impetus driving the protein engineering market.

Key players in the protein engineering market are creating innovative products using advanced technologies, such as the SUREtechnology platform, to improve the stability, efficacy, and manufacturability of therapeutic proteins. The SUREtechnology platform allows for precise modifications, facilitating the production of next-generation biologics with enhanced therapeutic properties, minimized side effects, and increased production efficiency. For example, in September 2023, KBI Biopharma, a US-based biotechnology company, introduced SUREmAb, an innovative solution developed on its SUREtechnology platform. This product focuses on the optimized, safe, and cost-effective development and manufacturing of monoclonal antibodies (mAb), addressing the growing demand for biopharmaceuticals. SUREmAb enables rapid progress from transfection to Research Cell Bank (RCB) in as little as nine weeks and allows for drug substance release within 11 months.

In July 2024, Fortifi, a US-based food processing company, acquired Les Innovations Mecaniques Alimentaires for an undisclosed amount. By incorporating LIMA into its operations, Fortifi aims to reinforce its leadership position in the food processing equipment market, boosting its competitiveness and market share. Les Innovations Mecaniques Alimentaires is a France-based manufacturer of protein processing equipment.

Major companies operating in the protein engineering market are Codexis Inc., GenScript Biotech Corporation, Abzena plc, Aragen Bioscience Inc., Enantis s.r.o., Creative BioMart, Twist Bioscience Corporation, Ginkgo Bioworks Inc., Amyris Inc., Absci Corporation, Generate Biomedicines Inc., ProteinQure Inc., Zymeworks Inc., Adimab LLC, Ichnos Sciences SA, Synthego Corporation, Evotec SE, Pieris Pharmaceuticals Inc., MacroGenics Inc., Adagene Inc.

North America was the largest region in the protein engineering market share in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the protein engineering market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the protein engineering market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The protein engineering market consists of revenues earned by entities by providing protein engineering services through use of enzymes, interleukins, and thrombolytics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.